Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1, Randomized, Double-Blind, Dose-Escalating Study of the Safety, Reactogenicity, and Immunogenicity of the AMA1-C1/Alhydrogel+CPG 7909 Vaccine for Plasmodium Falciparum Malaria in Children in Mali

NCT00740090 is registered in ClinicalTrials.gov with National Institute of Allergy and Infectious Diseases (NIAID) as lead sponsor.

NCT NCT00740090
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00740090 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1, Randomized, Double-Blind, Dose-Escalating Study of the Safety, Reactogenicity, and Immunogenicity of the AMA1-C1/Alhydrogel+CPG 7909 Vaccine for Plasmodium Falciparum Malaria in Children in Mali
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Phase
Phase 1
Overall status
Completed
Start date
August 11, 2008
Completion date
Not reported
Enrollment
200
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malaria, malaria infection